Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where A REMS Didn't Help: Sanofi Must Deal With Liver Injuries With Multaq

This article was originally published in The Pink Sheet Daily

Executive Summary

Company has sent a "Dear Dr." letter describing rare cases of liver problems and will also send additional data to FDA from the clinical trials.
Advertisement

Related Content

Multaq REMS May Be Revamped As Label Adds New Risks
EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
FDA Prepares To Update Drug-Induced Liver Injury Guidance
FDA Prepares To Update Drug-Induced Liver Injury Guidance
Sometimes It Takes Two NDAs For One Approval: Multaq Odyssey Shows FDA In Search Of Reassurance In Tricky Antiarrhythmic Field
Sometimes It Takes Two NDAs For One Approval: Multaq Odyssey Shows FDA In Search Of Reassurance In Tricky Antiarrhythmic Field

Topics

Advertisement
UsernamePublicRestriction

Register

PS071701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel